UF Center for Drug Evaluation and Safety
@UFCoDES
Followers
599
Following
539
Media
139
Statuses
753
Official account of the @UF Center for Drug Evaluation and Safety. @UFHealth @UFPharmacy #DrugSafety #RWE #RealWorldData #DataScience. RTs are not endorsements
Gainesville, FL
Joined June 2019
š·UPDATEš· CoDES will be transitioning from X to LinkedIn! Please follow our LinkedIn account for updates on our latest research, news, and more! As always, we look forward to continuing to translate big data into even bigger, healthier and safer outcomes!
linkedin.com
UF Center for Drug Evaluation and Safety | 312 followers on LinkedIn. We translate big data into even bigger, healthier and safer outcomes. | Established in 2019, the University of Florida Center for...
0
0
0
POP graduate student Henry Hung-Kai Chen places third in student abstract competition at ISPE Annual Meeting https://t.co/6BAUrERGpL
pharmacy.ufl.edu
Chen was the Third Place Winner of the Stanley A. Edlavitch Award, named after the society's first executive director.
0
0
3
UF Health researchers receive NIH R01 grant to develop social risk management tool for people living with dementia @Serena_JG
https://t.co/lG0kEFUqGk
pharmacy.ufl.edu
A team of UF Health researchers led by Serena Jingchuan Guo, M.D. Ph.D., aims to reduce health inequities faced by people living with dementia.
0
0
0
New publication by @UFCoDES trainee @SJugl1 in @LiebertPub āLegalization of Smokable Medical Cannabis and Changes in the Dispensed Amount of Ī-9 Tetrahydrocannabinol Per Patient | Cannabis and Cannabinoid Research https://t.co/Y60AniA7S5
@amiegoodin @AlmutWinterste1
liebertpub.com
Introduction: Floridaās medical cannabis (marijuana) program is among the largest in the United States. Smokable cannabis forms were not legally available in this program until 2019, and five years...
0
0
2
New publication by @AlmutWinterste1 and @Serena_JG in @IntPharmacoEpi Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremiā¦ https://t.co/xeacreG1C4
@UFPharmacy
pubmed.ncbi.nlm.nih.gov
Our machine learning model efficiently predicted the risk of LEA among diabetes patients undergoing canagliflozin treatment. The risk score may support optimized treatment decisions and thus improve...
0
1
2
New publication by @UFCoDES trainee @TangHuilin in @BioMedCentral ā Association of education attainment, smoking status, and alcohol use disorder with dementia risk in older adults: aā¦ https://t.co/Svgmpxg4Dk
@Serena_JG @UFPharmacy
pubmed.ncbi.nlm.nih.gov
Our studies identified important factors contributing to HTEs of education, smoking, and AUD on risk of all-cause dementia, suggesting an individualized approach is needed to address dementia...
0
0
1
New publication by @Serena_JG in Diabetes, Obesity and Metabolism ā Sodium-glucose cotransporter 2 inhibitors and the risk of #Parkinson disease in real-world patients with type 2 diabetes https://t.co/W6GKfukoWe
@UFPharmacy
pubmed.ncbi.nlm.nih.gov
Compared to DPP4 inhibitors, SGLT2 inhibitors were associated with a significantly lower risk of incident PD in older populations with T2D.
0
0
0
New publication co-authored by @segal_rich in @ADCESdiabetes Medication Engagement, Determinants of Health, and A1C Levels Among Adults With Type 2 Diabetes within a Tribal Health System https://t.co/5LsvlIljPO
@UFPharmacy
journals.sagepub.com
Purpose The purpose of this study was to examine the association between determinants of health, medication engagement, and A1C levels in adults with type 2 dia...
0
0
0
New publication by @UFCoDES trainee @tSHCw in @amcporgā Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptorāpositive/human epidermal growth factor... https://t.co/YCKct3OdnZ
jmcp.org
BACKGROUND: Abemaciclib was newly approved for hormone receptorāpositive (HR+), human epidermal growth factor receptor 2ānegative (HER2-) high-risk early breast cancer (EBC). Clinical guidelines...
0
1
1
New publication by @UFCoDES trainee @RiazMunaza in @JInternMedā Hospitalization after #hydroxychloroquine initiation in patients with heart failure with preserved #ejection fractionā¦ https://t.co/KSq1NRcHCo
@UFPharmacy
pubmed.ncbi.nlm.nih.gov
Among patients with HFpEF and autoimmune disease, initiation of HCQ use was associated with a decreased risk of HF-related and all-cause hospitalizations.
0
1
1
New publication by @UFCoDES trainee @TangHuilin in @movedisorder GlucagonāLike Peptideā1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A PopulationāBased Cohort Study https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.29992
0
0
0
New publication by @UFCoDES trainee @GraceWahaha in @JAMANetworkOpen #Injurious Fall Risk Differences Among Older Adults Being Treated for #Depression
https://t.co/JCTKTTn7bF
@jennyciganic @amiegoodin
@UFPharmacy
jamanetwork.com
This cohort study assesses the association between the risk of fall-related injuries and first-line treatments for depression among older US adults with depression.
0
0
0
New publication co-authored by @SteveSmithUF in @AMIAinformatics - Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program https://t.co/cG6o9uXclt
@UFPharmacy
academic.oup.com
AbstractBackground. Hypertension (HTN) remains a significant public health concern and the primary modifiable risk factor for cardiovascular disease, which
0
0
0
New publication co-authored by @AlmutWinterste1 in @ASCPT_ClinPharm ā Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators https://t.co/SCzC2bfzp4
@UFPharmacy
ascpt.onlinelibrary.wiley.com
Opioid prescribing for postoperative pain management is challenging because of inter-patient variability in opioid response and concern about opioid addiction. Tramadol, hydrocodone, and codeine...
0
1
1
New publication co-authored by @AlmutWinterste1 in @ASCPT_ClinPharm -Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry ā Informing optimal antiplatelet strategies https://t.co/3cssePRE8H
@UFPharmacy
ascpt.onlinelibrary.wiley.com
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is indicated after percutaneous coronary intervention (PCI) to reduce the risk of...
0
1
1
New publication co-authored by @Serena_JG in American Journal of Cardiovascular Drugs ā#COVID-19 Diagnosis, Oral #Anticoagulation, and #Stroke Risk in Patients with Atrial Fibrillation https://t.co/0vw7RVYI1n
@UFPharmacy
pubmed.ncbi.nlm.nih.gov
In a nationwide sample of patients with established AF, we found the relative increase in stroke risk associated with COVID-19 was independent of OAC use.
0
0
0
New publication by @amiegoodin in @IntPharmacoEpi ā Risk of #Suicidal Ideation and Behavior Following Early-Onset #Idiopathic Restless Legs Syndrome Treatment https://t.co/CMa7N7tBK3
@UFPharmacy
pubmed.ncbi.nlm.nih.gov
Incidence rates for suicidal ideation and behavior were higher among the gabapentinoid group, although increased risk was not detected after adjustment. A possible signal cannot be ruled out given...
0
0
0
New publication by @AlmutWinterste1 @amiegoodin in @KargerPublisher ā Reasons for Use and Perceived Effects of #Medical #Cannabis: A Cross-Sectional Statewide Survey https://t.co/BT6dCtlt1y
@UFPharmacy
karger.com
Abstract. Introduction: Medical cannabis (MC) is available upon certification for one of several qualifying conditions in Florida, USA. Previous studies suggested that some people seek cannabis for...
0
0
1
Dr. Riazās heart failure study was recognized at the 2024 ISPOR Conference. @RiazMunaza, Ph.D., is a 2023 graduate of the University of Florida College of Pharmacyās department of pharmaceutical outcomes and policy. @UFPharmacy
0
1
3
The University of Florida College of Pharmacy- Department of Pharmaceutical Outcomes & Policy congratulates @SteveSmithUF who was promoted to associate professor on July 1, 2024. @UFPharmacy
0
0
5